Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Forced expression of miR-196b significantly delays MLL-fusion-mediated leukemogenesis in primary bone marrow transplantation through suppressing Hoxa9/Meis1 expression.
|
22353710 |
2012 |
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hoxa9 and Meis1 also cooperate to induce aggressive AML with high Flt3 expression in mice, suggesting an important role for Flt3 in Hoxa9/Meis1-induced leukemogenesis.
|
27617578 |
2017 |
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AML-associated loss-of-function mutations of <i>MIR142</i> disrupt this negative signaling pathway, resulting in sustained <i>HOXA9/A10</i> expression in myeloid progenitors/myeloblasts and ultimately contributing to leukemic transformation.<b>Significance:</b> These findings provide mechanistic insights into the role of miRNAs in leukemogenesis and hematopoietic stem cell function.<i></i>.
|
29724719 |
2018 |
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis.
|
23894305 |
2013 |
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we identified PBX2, a well-known homeodomain protein whose aberrant expression enhances HoxA9-dependent leukemogenesis, as a novel let-7c target that may contribute to the AML phenotype.
|
22964640 |
2013 |
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Functional relevance of GPR56 expression was validated in mice, in which co-expression of Gpr56 significantly accelerated HOXA9-induced leukemogenesis and vice versa knockdown of Gpr56 delayed onset of HOXA9/MEIS1-induced AML.
|
27063597 |
2016 |
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the N-terminus was required for proliferation and leukemogenesis in vitro and in vivo through upregulation of HoxA9, HoxA10 and Meis2.
|
25401736 |
2014 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our data indicate that both truncated and full-length forms of HOXA9 are highly expressed in human MLL-rearranged leukemia, and the truncated isoform of HOXA9 might also play an oncogenic role by cooperating with canonical HOXA9 in cell transformation and leukemogenesis.
|
22633751 |
2012 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggest that PBX3 is a critical cofactor of HOXA9 in leukemogenesis, and targeting their interaction is a feasible strategy to treat presently therapy resistant CA-AML (eg, MLL-rearranged leukemia) in which HOXA/PBX3 genes are overexpressed.
|
23264595 |
2013 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These include upregulation of genes involved in the transforming growth factorbeta pathway, fetal hemoglobin genes, leptin receptor, sorcin, tissue inhibitor of metalloproteinase 1, the neuroepithelial cell transforming gene 1 and downregulation of selenoprotein P. Additionally, genes associated with early hematopoietic stem cells (HSC) and leukemogenesis such as HoxA9 and MEIS1 were transcriptionally activated.
|
17252012 |
2007 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results show that major differentiation factors of the NK-cell lineage, including HOXA9, HOXA10 and ID2, were (de)regulated via PRC2 which therefore contributes to T-cell leukemogenesis.
|
20565746 |
2010 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
RNA export factor RAE1 contributes to NUP98-HOXA9-mediated leukemogenesis.
|
21467841 |
2011 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This suggested that the NUP98-HOXA9 fusion induced a preleukemic phase, and other factors were required for complete leukemogenesis.
|
15454493 |
2005 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This resistance to apoptotic stimuli, coupled with the previously reported ability to suppress multiple myeloid differentiation pathways, would provide a strong selective advantage to Meis1-HoxA9 coexpressing cells in vivo, leading to leukemogenesis.
|
15479723 |
2005 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The protein encoded by the NUP98-HOXA13 fusion gene is similar to that encoded by NUP98-HOXA9, and the expression pattern of the HOXA13 gene in leukemic cell lines is similar to that of the HOXA9 gene, suggesting that the NUP98-HOXA13 fusion protein may play a role in leukemogenesis through a mechanism similar to that of the NUP98-HOXA9 fusion protein.
|
12112533 |
2002 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
As both HLX1 and HOXA9 are oncogenes implicated in leukemogenesis, we discuss the implications that the collaboration between Homeobox proteins and PRCs has for senescence and cancer.
|
24067365 |
2013 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis.
|
30622285 |
2019 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we provide evidence of phenotypic and functional hierarchy in MN1-induced leukemic cells, characterise contributions of Hlf, Hoxa9 and Meis1 to in vitro leukemic properties, and reveal Meis2 as a novel player in MN1-induced leukemogenesis.
|
28960191 |
2017 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these results suggest that specific recruitment of MLL1 requires multiple interactions and is a precondition for stable recruitment of MLL1 fusion proteins to HoxA9 in leukemogenesis.
|
20541448 |
2010 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our studies thus establish that mistargeting of hDOT1L to Hoxa9 plays an important role in MLL-AF10-mediated leukemogenesis and suggests that the enzymatic activity of hDOT1L may provide a potential target for therapeutic intervention.
|
15851025 |
2005 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrant fusion proteins involving the MLL histone methyltransferase (HMT) lead to recruitment of DOT1L, to a multi-protein complex resulting in aberrant methylation of histone H3 lysine 79 at MLL target genes, and ultimately enhanced expression of critical genes for hematopoietic differentiation, including HOXA9 and MEIS1, and as such defines the established mechanism for leukemogenesis in MLL-rearrangement (MLL-r) leukemias.
|
28229434 |
2017 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Homeobox genes HOXA9 and MEIS1 are evolutionarily conserved transcription factors with essential roles in both hematopoiesis and leukemogenesis.
|
26059450 |
2015 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis.
|
30270123 |
2018 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed global DNA binding of MEIS1 in leukemic cells as well as gene expression alterations in MEIS1-deficent cells and identified synaptotagmin-like 1 (Sytl1, also known as Slp1) as the MEIS1 target gene that cooperates with Hoxa9 in leukemogenesis.
|
27018596 |
2016 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In many cases, HOXA9 has been shown to be necessary for maintaining leukemic transformation; however, the molecular mechanisms through which it promotes leukemogenesis remain elusive.
|
26028034 |
2016 |